Introduction
Adenosine, an ubiquitous nucleoside that comes from the dephosphorylation of ATP, acts on G protein-coupled adenosine receptors (AR), named A 1 , A 2A , A 2B and A 3 , depending on the pharmacological properties of the receptor subtypes. 1 Each AR has a specific tissue distribution, ligand affinity, and signal transduction mechanism. Because of their presence on nearly every cell type, adenosine receptors have been obvious targets for the development of new drugs for more than three decades. 2 The A 1 adenosine receptors (A 1 AR), highly expressed in heart, brain, dorsal spinal cord, adipose tissue and kidney, 3 particularly raised our attention. According to the recent literature the best approach for the discovery of new AR agonists consists of N 6 modifications or introduction of selective functionalization at 2position of the adenine moiety and at the 3¢-, 4¢-or 5¢-position of the ribose part. Among them N 6 -chlorocyclopentyladenosine (CCPA) and N 6 -cyclopentyladenosine (CPA) have been reported as being highly selective A 1 AR agonists. 4 On the other hand, reported AR antagonists are usually derivatives of xanthines such as caffeine or theophylline. 5 Thus, having drugs that modulate A 1 AR at one's disposal could be interesting in different therapeutic areas, including heart failure, diuresis, 6 heart arrhythmia, 7 glucose tolerance, 8 cognitive diseases 9 and contrast media-induced acute renal failure. 10 Nevertheless, the modified adenosine approach is hampered by the presence of adenosine deaminase (ADA) involved in purines metabolism that irreversibly converts adenosine to the less active inosine nucleoside by selective C-6 deamination. To circumvent this drawback, the design of new analogues resistant to ADA bearing a non metabolisable C-6 amino group is needed. a Aix-Marseille Université, Institut des Sciences Moléculaires de Marseille, iSm2-UMR CNRS 6263, Centre Saint Jérôme, Service 532, 13397, Marseille Cedex 20, France. E-mail: jl.parrain@univ-cezanne.fr; Fax: +33 4 91 28 91 87; Tel: +33 4 91 28 89 14 In this context, we propose an expeditious approach based on click-chemistry of specifically functionalized nucleoside analogues starting from commercially available inosine.
New methods for the synthesis of C6 purine derivatives have been widely developed for two decades. Advances in this field employ nucleophilic displacement (S N Ar), 11 and the area of organometallic cross-coupling 12 such as Suzuki-Miyaura, 13 Sonogashira, 14 Stille, 15 and Buchwald-Hartwig 16 coupling reactions. Alternatively, the discovery 17 of the dramatic acceleration of the copper(I) mediated Huisgen 1,3-dipolar cycloaddition of alkyne and azides to yield 1,2,3-triazoles has generated the synthesis of a plethora of new compounds and has accelerated advances in areas ranging from drug discovery to material sciences. 18 Although a number of 1,2,3-triazole nucleoside derivatives has been described, 19 most involve introduction of 1,2,3-triazole at C2, 20 and C8 21 or at the sugar moiety. 22 To the best of our knowledge, when we started the project, this "click reaction" was unexploited for the synthesis of N 6 -aminopurine derivatives. 23 As part of our ongoing research towards the synthesis of biologically active adenosine derivatives, 24 we have developed this approach for a rapid access to new N 6 nucleoside derivatives. We describe herein the synthesis, the A 1 binding affinities and the biological evaluation of a novel series of new C-6 1,2,3-triazole substituted purine derivatives 1 via microwave assisted 1,3-dipolar cycloaddition. adenosine 2 can be synthesized via nucleophilic displacement reaction of the electrophilic nucleoside 3 by sodium azide. 6-Chloropurine riboside (3) was prepared in three steps (90% overall yield) according to a previously reported procedure from the commercially available inosine. 27 However, the S N Ar reaction of 3 using the reported conditions did not furnish the corresponding azide 2. Despite numerous attempts to modify the reaction conditions (lower temperature, microwave irradiation or protection of the alcohol function on the sugar part as an acetate or acetal), 2 was always detected only in trace amount. Finally replacement of sodium azide by lithium azide (DMF, rt, 2 days) 28 led, in 30% yield, to the formation of 2 in equilibrium with its tetrazolo tautomeric form 2¢. 25, 28, 29 Even if 2 was obtained in low yield, the copper(I)-mediated Huisgen 1,3-dipolar cycloaddition was then investigated (Scheme 2). Phenylacetylene was chosen as a benchmark substrate and the reaction was initially performed with sodium ascorbate, CuSO 4 ·5H 2 O in DMF for 12 h at 80 • C (conditions A). Unfortunately, the desired 1,4-disubstituted 1,2,3-triazole 1 (R=Ph) was never observed. Adenosine, resulting from the reduction of the azido function of 2 into the corresponding amine, was isolated in 45% yield as the main reaction product. This kind of reduction was already described by Frieden et al. and can be explain by a thermal decomposition of the azido function to the corresponding nitrene, which evolved into the amine formation. 25 Whatever the conditions used to perform the 1, with tetrabutylammonium fluoride 31 to yield the terminal alkyne 4 in 43% yield.
The Cu(I)-catalyzed 1,3-dipolar cycloaddition reaction was next studied. In an initial experiment (Scheme 4), the alkynyl derivative 4 was treated with benzyl azide 7a in dry DMF at 90 • C in the presence of copper(II) and sodium ascorbate under microwave conditions for 30 min. We were pleased to find that these conditions afforded the triazole derivative 8a in 58% yield thus validating this new approach (Scheme 4). In order to examine the scope of this approach, the [3+2]-cycloaddition was then performed with a range of different azides 7b-j (Scheme 4). The latter were prepared according to a safe literature procedure developed by Varma et al. 32 based on a nucleophilic substitution reaction of alkyl halides by sodium azide in water using microwave-assisted heating. The 1,3dipolar cycloaddition has then allowed the formation of several new C-6 1,2,3-triazole adenosine derivatives 8b-j in good yields (up to 82%) and with a total regioselectivity. Interestingly, when the reaction was performed with 1,3diazidopropane 7k, a separable mixture of bis-C6-1,2,3-triazole bis-adenosine 8k and mono cycloadduct derivative 8l were obtained in moderate yield (respectively 24 and 16%, Scheme 5). At last, deprotection of the acetate functions of the sugar part under basic condition (NH 3 , MeOH) led to the formation of the corresponding compounds 9a-k in excellent yields (up to 99%, Scheme 4 and 5). unprecedented molecules to modulate cAMP production in mammalian Chem-3 cells that over expressed A 1 ARs was first tested. Indeed, agonists of A 1 AR are believed to decrease the cAMP production whereas antagonists display the opposite effect.
As a matter of fact 9e, 9f, 9h and 9i increased cAMP production in cell culture, in a dose-dependent manner acting as antagonists of the A 1 AR (Table 1) , while 9j and 9k decreased cAMP production acting as agonists ( Table 1 ). The IC 50 of compounds was also evaluated, using binding assay on cell membranes. IC 50 of antagonist compounds range between 0.29 mM and 1.5 mM and between 11 mM and 42 mM for agonist compounds (Table 1) . Even if these molecules have weaker affinity when compared to the well known A 1 AR antagonist DPCPX, their biological effects occur at reasonable concentrations.
Compounds 9a, 9b, 9c, 9d and 9g had an IC 50 for A1AR binding >100 mM and all compounds tested had an IC 50 for A 2A adenosine receptor binding >50 mM (data not shown). While nitroaromatic compounds have been reported to have A 1 AR antagonist properties, 33 interestingly, 9j exhibits agonist properties. It is also interesting to note that nitroaromatic compounds were known to act via the inhibition of NO synthase and cGMP modulation. 34
Conclusions
In summary we have reported the synthesis of new C-6 1,2,3triazole adenosine derivatives via microwave assisted 1,3-dipolar cycloaddition as key step. Among them, four compounds expressed antagonist properties, while two expressed agonist properties, basing on cAMP production on A 1 AR. Their biological effects were obtained at reasonable concentrations.
Experimental
All reactions sensitive to oxygen and moisture were carried out in oven-dried glassware under a slight positive pressure of argon unless otherwise noted. Reagents and solvents were commercial grades and were used as supplied. N,N-dimethylformamide was distilled from calcium hydride and stored over calcium hydride. THF was obtained from a Solvent Purification System. Triethylamine was distilled from KOH prior to use. Analytical thin layer chromatography (TLC) was performed on Merck precoated analytical plates, 0.25 mm thick, silica gel 60 F254. Flash column chromatography was performed on Merck Kieselgel 40-63 mm. 1 H NMR and 13 C NMR spectra were recorded on an AC300 using the deuterated solvent as internal deuterium lock. Chemical Table 1 Effects of compounds on cAMP production and on [ 3 H] DPCPX displacement or [ 3 H] CPA displacement on Chem 3 cells that overexpress the A1 AR. IC 50 for cAMP inhibition was defined as the concentration of compound that induces half of the maximal cAMP inhibition. EC 50 for cAMP production was defined as the concentration of compound that induces half of the maximal cAMP production. IC 50 for DPCPX or CPA displacement was defined as the concentration of competing ligand which displaces 50% of [ 
5.5 ± 0.9 10 -7 2.9 ± 0.8 10 -7 Antagonist 9f
7 ± 2 10 -7 15 ± 4 10 -7 Antagonist 9g
>10 -5 -9h
6 ± 2 10 -6 6 ± 1.8 10 -7 Antagonist 9i
7 ± 2 10 -7 4 ± 2.9 10 -7 Antagonist 9j
1 ± 0.6 10 -6 42 ± 11 10 -6 Agonist 9k
0.5 ± 0.3 10 -6 11 ± 4 10 -6 Agonist DPCPX
3.8 ± 0.5 10 To a stirred solution of chloroinosine 3 (400 mg, 1.38 mmol) in dry DMF was added lithium azide (750 mg, 15.2 mmol). The reaction was stirred at room temperature for 60 h then the solvent was removed under vacuum. The crude product was recrystallized from methanol to give 2 (120 mg, 30%). General procedure for the synthesis of compounds 8a-l.
A mixture of acetylene 4 (70 mg, 0.17 mmol), benzyl azide (0.24 mmol), sodium ascorbate (10 mg, 0.051 mmol) and copper sulfate pentahydrate (2 mg) in dry DMF (2 mL) was subjected to microwave irradiation for 30 min at a temperature of 90 • C. The reaction mixture was then concentrated, extracted with dichloromethane and the residue was purified by column chromatography using dichloromethane-methanol as eluent to afford the triazole derivatives 8a-l. (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(6-(1-(4-methoxybenzyl)-1H -1,2,3-triazol-4-yl)-9H -purin-9-yl) (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(6-(1-(3,4-dichlorobenzyl)-1H -1,2,3-triazol-4-yl) 
General procedure for the synthesis of compounds 9a-9k
A solution of NH 3 /MeOH (0.7 mL) was added over triacetate 9 (70 mmol). The mixture was stirred overnight at room temperature and followed by TLC. Once reaction was complete by TLC, the mixture was evaporated under reduced pressure and purified by column chromatography using dichloromethane-methanol (85/15) as eluent to afford the triazole derivatives 9a-9k. (2R,3R,4S,5R)-2-(6-(1-benzyl-1H-1,2,3-triazol-4-yl 3R,4S,5R) -2 -(6 -(1 -(4 -chlorobenzyl) -1H -1,2,3 -triazol-4 the presence of 10 mM of unlabeled ligand. EC 50 was defined as the concentration of drug that induce the half maximal effects.
